Anonymous User
Login / Registration

Gastroenterologie
a hepatologie

Gastroenterology and Hepatology

Gastroent Hepatol 2016; 70(5): 457–462. doi:10.14735/amgh2016457.

Ursodeoxycholic acid

Jan Juřica1

+ Affiliation

To read this article in full, please register for free on this website.

Benefits for subscribers

Benefits for logged users

Literature

1. Hempfling W, Dilger K, Beuers U. Ursodeoxycholic acid – adverse effects and drug interactions. Aliment Pharmacol Ther 2003; 18 (10): 963–972.
2. Beuers U, Trauner M, Jansen P et al. New paradigms in the treatment of hepatic cholestasis. From UDCA to FXR, PXR and beyond. J Hepatol 2015; 62 (Suppl 1): S25–S37. doi: 10.1016/j.jhep.2015.02.023.
3. Roma MG, Toledo FD, Boaglio AC et al. Ursodeoxycholic acid in cholestasis: linking action mechanisms to therapeutic applications. Clin Sci (Lond) 2011; 121 (12): 523–544. doi: 10.1042/CS20110184.
4. Chiang JY. Bile acids: regulation of synthesis. J Lipid Res 2009; 50 (10): 1955–1966. doi: 10.1194/jlr.R900010-JLR200.
5. Státní ústav pro kontrolu léčiv. Souhrn údajů o přípravku Ursosan 2014. [online]. Dostupné z: www.sukl.cz/modules/medication/detail.php?code=00138 08&tab=texts.
6. Doporučený postup České hepatologické společnosti ČLS JEP. PBC (primární biliární cirhóza) a PSC (primární sklerozující cholangoitida). Česká hepatologická společnost 2010: 1–19. [online]. Dostupné z: www.ces-hep.cz/file/325/doporuceny-postup-chs-pbc-a-psc.pdf.
7. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 2009; 51 (2): 237–267. doi: 10.1016/j.jhep.2009.04.009.
8. Nunes D. Dissolution therapy for the treatment of gallstones. UpToDate. [online]. Available from: www.uptodate.com/contents/dissolution-therapy-for-the-treat-ment-of-gallstones.
9. Guarino M, Cocca S, Altomare A et al. Ursodeoxycholic acid therapy in gallbladder disease, a story not yet completed. World J Gastroenterol 2013, 19 (31): 5029–5034. doi: 10.3748/wjg.v19.i31.5029.
10. Shah H, Mandukhal S, Gilani A et al. Effect of ursodeoxycholic acid (UDCA) therapy on gallbladder motility in cholesterol gallstone patients. Am J Gastroenterol 2012; 107 (Suppl 1): S73.
11. Chen W, Liu J, Gluud C. Bile acids for viral hepatitis. Cochrane Database Syst Rev 2007; 4: CD003181.
12. Wijaya I. The Role of ursodeoxycholic acid in acute viral hepatitis: an evidence-based case report. Acta Med Indones 2015, 47 (4): 352–357.
13. Verma S, Kaplowitz N. Diagnosis, management and prevention of drug-induced liver injury. Gut 2009, 58 (11): 1555–1564. doi: 10.1136/gut.2008.163675.
14. Sabariah NH, Siti MS, Nor AC et al. Cholestatic hepatitis secondary to carbamazepine treatment with ursodeoxycholic acid – a case report. Trop J Pharm Res 2014; 13 (10): 1745–1747.
15. Xiang Z, Chen YP, Ma KF et al. The role of ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic review. BMC Gastroenterol 2013; 13: 140. doi: 10.1186/1471-230X-13-140.
16. Carr RM, Reid AE. FXR agonists as therapeutic agents for non-alcoholic fatty liver disease. Curr Atheroscler Rep 2015, 17 (4): 500. doi: 10.1007/s11883-015-0500-2.
17. Georgescu EF, Georgescu M. Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study. J Gastrointestin Liver Dis 2007; 16 (1): 39–46.
18. Ratziu V. Treatment of NASH with ursodeoxycholic acid: pro. Clin Res Hepatol Gastroenterol 2012; 36 (Suppl 1): S41–S45. doi: 10.1016/S2210-7401 (12) 70020-7.
19. Lazaridis KN, Gores GJ, Lindor KD. Ursodeoxycholic acid ‚mechanisms of action and clinical use in hepatobiliary disorders‘. J Hepatol 2001; 35 (1): 134–146.
20. Fickert P, Zollner G, Fuchsbichler A et al. Effects of ursodeoxycholic and cholic acid feeding on hepatocellular transporter expression in mouse liver. Gastroenterol 2001; 121 (1): 170–183.
21. Zollner G, Wagner M, Moustafa T et al. Coordinated induction of bile acid detoxification and alternative elimination in mice: role of FXR-regulated organic solute transporter-alpha/beta in the adaptive response to bile acids. Am J Physiol Gastrointest Liver Physiol 2006; 290 (5): G923–G932.
22. Zollner G, Wagner M, Trauner M. Nuclear receptors as drug targets in cholestasis and drug-induced hepatotoxicity. Pharmacol Ther 2010; 126 (3): 228–243. doi: 10.1016/j.pharmthera.2010.03.005.
23. Micheline D, Emmanuel J, Serge E. Effect of ursodeoxycholic acid on the expression of the hepatocellular bile acid transporters (Ntcp and bsep) in rats with estrogen-induced cholestasis. J Pediatr Gastroenterol Nutr 2002; 35 (2): 185–191.
24. Schuetz EG, Strom S, Yasuda K et al. Disrupted bile acid homeostasis reveals an unexpected interaction among nuclear hormone receptors, transporters, and cytochrome p450. J Biol Chem 2001; 276 (42): 39411–39418.
25. Concepcion AR, Lopez M, Ardura-Fabregat A et al. Role of AE2 for pH (i) regulation in biliary epithelial cells. Front Physiol 2014; 4: 413. doi: 10.3389/fphys.2013.00413.
26. Buryova H, Chalupsky K, Zbodakova O et al. Liver protective effect of ursodeoxy- cholic acid includes regulation of ADAM17 activity. BMC Gastroenteroly 2013, 13: 155. doi: 10.1186/1471-230X- 13-155
27. Azzaroli F, Mehal W, Soroka CJ et al. Ursodeoxycholic acid diminishes Fas-ligand-induced apoptosis in mouse hepatocytes. Hepatology 2002; 36 (1): 49–54.
28. Poupon R. Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action. Clin Res Hepatol Gastroenterol 2012, 36 (Suppl 1): S3–S12. doi: 10.1016/S2210-7401 (12) 70015-3.
29. Corpechot C, Carrat F, Bonnand AM et al.The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology 2000; 32 (6): 1196–1199.
30. Tay J, Tinmouth A, Fergusson D et al. Systematic review of controlled clinical trials on the use of ursodeoxycholic acid for the prevention of hepatic veno-occlusive disease in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007; 13 (2): 206–217.
31. Dynamed. Ursodiol. In: EBSCO 2016. [online]. Available from: http: //web.a.ebs cohost.com/dynamed/detail?vid=2&sid=f26b9687-6f75-4976-afcd-e8f705 da8691%40sessionmgr4009&hid=4206& bdata=JnNpdGU9ZHluYW1lZC1saXZlJnNjb3BlPXNpdGU%3d#AN=526120&db=dme.
32. Crosignani A, Setchell KD, Invernizzi P et al. Clinical pharmacokinetics of therapeutic bile acids. Clin Pharmacokinet 1996; 30 (5): 333–358.
33. Stiehl A, Rudolph G, Sauer P et al. Billiary secretion of bile acids and lipids in primary sclerosing cholangitis – influence of cholestasis and effect of ursodeoxycholic acid treatment. J Hepatol 1995, 23 (3): 283–289.
34. Sackmann M, Pauletzki J, Aydemir U et al. Efficacy and safety of ursodeoxycholic acid for dissolution of gallstone fragments – comparison with the combination of ursodeoxycholic acid and chenodeoxycholic acid. Hepatology 1991; 14 (6): 1136–1141.
35. Singh S, Khanna S, Pardi DS et al. Effect of ursodeoxycholic acid use on the risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease. A systematic review and meta-analysis. Inflamm Bowel Dis 2013; 19 (8): 1631–1638. doi: 10.1097/MIB. 0b013e318286fa61.
36. Gabzdyl E, Schlaeger JM. Intrahepatic cholestasis of pregnancy a critical clinical review. J Perinat Neonatal Nurs 2015; 29 (1): 41–50. doi: 10.1097/JPN.0000000000000077.
37. Rudi J, Schönig T, Stremmel W. Therapy with ursodeoxycholic acid in primary biliary cirrhosis during pregnancy. Z Gastroenterol 1996; 34 (3): 188–191.

Credited self-teaching test